Overview
BioTAB Healthcare provides in-home Pneumatic Compression Devices prescribed by clinicians to treat lymphatic, wound, and circulatory disorders. The devices deliver timed compression cycles at home to move fluid, reduce swelling, improve circulation, and speed healing under clinician guidance. It differentiates itself through a patient-first, family-owned approach that includes in-home setup, ongoing support, and end-to-end administration of paperwork and insurance to simplify access, often for doctor-prescribed devices covered by programs like the VA. The goal is to improve patients’ quality of life by making comfortable, effective home therapy accessible and easy to use.
Work here?Claim your company
Simplify's take
What believers are saying
- BioTAB attended St. Louis VAMC Industry Day on May 27, 2026.
- It posted roughly 13 open roles in October 2026, signaling active growth.
- Its updated 2026 website emphasizes clinically proven, condition-specific compression therapy.
What critics are saying
- BioTAB sued West Side Medical Supply in March 2025 over trade-secret leakage and channel churn.
- Indeed reviews in 2026 flag commission-only pay, weak transparency, and thin training.
- If the VA contract lapses after September 2030, BioTAB’s core revenue engine collapses.
What makes BioTAB Healthcare unique
- BioTAB’s VA contract runs through September 14, 2030, anchoring federal distribution.
- It bundles pumps, in-home setup, paperwork, and ongoing patient support.
- Its devices target lymphedema, venous ulcers, PAD, and chronic venous insufficiency.
Help us improve and share your feedback! Did you find this helpful?